Ashwagandha Cortisol Meta-analysis: What the Evidence Says

Quick Answer

Ashwagandha Cortisol Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 systematic review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• For example,evaluated nine randomized controlled trials by meta-analysis, and found that the scores of Perceived Stress Questionnaire (PSS), Anxiety Score (HAS) and serum cortisol levels were significantly reduced, indicating that it has a significant anti-pressure effect. [Zhu XiaoLing (2026); evidence level 1]
• A study involving 80 healthy subjects aged 18-45&#160;years showed that, compared with the placebo group, the Ashwagandha-supplemented group significantly improved bench press and leg lift strength, arm circumference and chest circumference, thigh circumference, and maximum oxygen uptake (VOmax) (p < 0.05). [Zhu XiaoLing (2026); evidence level 1]
• Background: Standardised Ashwagandha root extract (SARE), characterised by its content of bioactive withanolides, is widely used for its antioxidant and adaptogenic properties; however, recent case reports have raised safety concerns, primarily involving non-standardised or multi-ingredient formulations. [Coope OC (2026); evidence level 1]
• This systematic review evaluated the safety and tolerability of SARE in healthy adults, with a focus on clinical biomarkers and adverse event reporting. [Coope OC (2026); evidence level 1]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For ashwagandha cortisol meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Zhu XiaoLing (2026). Effects of Withania somnifera (L.) Dunal (Ashwagandha) on cognitive and physical function in adults: a systematic review and meta-analysis. DOI: 10.3389/fphar.2026.1799467. PMCID: PMC13199302. PMID: 42199854. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13199302/
• Coope OC (2026). Back to the Roots: Safety and Tolerability of Standardised Ashwagandha (<i>Withania somnifera</i>) Root Extract in Healthy Adults-A Systematic Review of Biomarkers and Adverse Events.. DOI: 10.3390/ph19050725. PMCID: PMC13209861. PMID: 42198398. https://pmc.ncbi.nlm.nih.gov/articles/PMC13209861/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.